Navigation Links
Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
Date:9/25/2007

hibition of this receptor is thought to be related to multiple processes that drive tumour growth and spread, including tumour cell proliferation, tumour cell survival, angiogenesis, and the formation of bone metastases.(2)

Notes to Editors

About Prostate Cancer

Prostate cancer primarily affects men over the age of 50.(3) It is the most commonly diagnosed male cancer in many western countries and its incidence is increasing. Worldwide, more than 670,000 men are diagnosed with prostate cancer every year, accounting for one in nine of all new cancers in men. Prostate cancer is the second most common cancer in men after lung cancer.(4) HRPC affects approximately 60,000 new patients in the US alone each year.(5)

About AstraZeneca

AstraZeneca is a major international health care business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of health care services. It is one of the world's leading pharmaceutical companies with health care sales of $26.475 billion and leading positions in sales of gastrointestinal, cardiovascular, neuroscience, respiratory, oncology, and infection products. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4 Good Index.

For more information visit:

http://www.astrazeneca-us.com

http://www.prostateinfo.com

References:

(1) James, M.D. ZD4054, a potent, specific endothelin A receptor antagonist, improves overall survival in pain-free or mildly symptomatic patients with hormone-resistant prostate cancer (HRPC) and bone metastases.

(2) Morris, C.D. et al. Specific inhibition of the endothelin A receptor with ZD4054: clinical and pre-clinical evidence. British Journal of Cancer. 2005: 92

(3) Kirby RS et al. Prostate cancer and sexual function. Prostate Cancer and Prosta
'/>"/>

SOURCE AstraZeneca
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Living in the Unreal World: A Survival Guide for Entrepreneurs
2. The Top 10 Musts That Should Be in Your Business Survival Kit
3. Wisconsin Manufacturing - demise or survival?
4. University Consortium Enables Transformation and Survival for Wisconsin Businesses
5. Wisconsin Assembly passes capital investment bill, revised CAPCO program not presented
6. Protocol for RNA Isolation Using TRIzol Reagent with Phase Lock Gel-Heavy
7. Protocol for RNA Isolation Using TRIzol Reagent with Phase Lock Gel-Heavy
8. Easy preparation of total RNA from cultured cells with TRIzol and Eppendorf Phase Lock Gel
9. Identification of cells in S phase using the Cell Proliferation Fluorescence Kit and IN Cell Analyzer 1000
10. Direct Monitoring of Solid-Phase Peptide Synthesis by MALDI-TOF MS
11. Separation and Quantitation of R and S Enantiomers using Normal Phase Chromatography on an API 3000 LC/MS/MS System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... Poway, CA (PRWEB) , ... July 28, 2015 , ... ... by a live stem cell credentialing course to local area veterinarians. , The tour ... RACE approved CE units at no charge) at VetStem’s Poway facility. Staff members are ...
(Date:7/28/2015)... NEW YORK , July 28, 2015 ... "Company"), a diversified life sciences company, today announced that ... authorized shares of common stock of the Company from ... held on July 27, 2015 at the Law Offices ... Meeting").   At the Special Meeting, there were 480,655,929 shares ...
(Date:7/28/2015)... 28, 2015  Moerae Matrix Inc. announced today ... trial with MMI-0100, a first-in-class inhibitor of MAPKAP ... pulmonary disorders characterized by inflammation and fibrosis.  The ... , is a double-blind, two-way cross-over design ... and tolerability of MMI-0100 when given via inhalation ...
(Date:7/28/2015)... 2015 CSL Behring announced today ... for review the company,s Biologics License Application (BLA) for ... the treatment of hemophilia A. In the pivotal clinical ... Hemophilia A is a congenital bleeding disorder ... affected patients are male. People with hemophilia A may ...
Breaking Biology Technology:VetStem Biopharma weekly veterinary continuing education classes and GMP manufacturing facility tour 2Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 2Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 3Moerae Initiates Lipopolysaccharide (LPS) Challenge Study of Inhaled MMI-0100 for Pulmonary Disease Following Encouraging Safety and Tolerability Observed in Single Ascending Dose Phase 1 Study 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 3
... Bio-,Pharmaceutical Technology, Inc (OTC Bulletin Board: HFGB), a ... raw materials,for use in pharmaceutical, nutraceutical and food ... for the three and six month periods,ended June ... 2008, sales of our products increased,substantially. Revenue received ...
... 14 /Xinhua-PRNewswire-FirstCall/ -- China Sky One,Medical, Inc. ... (Amex: CSY ), a,leading fully integrated ... the People,s Republic of China ("PRC"), today,announced ... for the treatment,and prevention of rheumatic disease., ...
... Inc. (Nasdaq: ADLS ), a biopharmaceutical company ... drugs in the,therapeutic areas of infection, cancer and ... second quarter ended June 30, 2008., (Logo: ... the three months was $3.4 million or ($0.09) ...
Cached Biology Technology:Huifeng Bio-Pharmaceutical (HFGB) Reports over $5 Million in Gross Sales; Record Results for the First Half of 2008 2China Sky One Medical, Inc. Develops Nasal Spray for Rheumatic Disease 2China Sky One Medical, Inc. Develops Nasal Spray for Rheumatic Disease 3Advanced Life Sciences Announces Second Quarter 2008 Financial Results 2Advanced Life Sciences Announces Second Quarter 2008 Financial Results 3Advanced Life Sciences Announces Second Quarter 2008 Financial Results 4Advanced Life Sciences Announces Second Quarter 2008 Financial Results 5Advanced Life Sciences Announces Second Quarter 2008 Financial Results 6Advanced Life Sciences Announces Second Quarter 2008 Financial Results 7Advanced Life Sciences Announces Second Quarter 2008 Financial Results 8Advanced Life Sciences Announces Second Quarter 2008 Financial Results 9Advanced Life Sciences Announces Second Quarter 2008 Financial Results 10
(Date:6/30/2015)... 2015 To bolster its efforts and commitment to ... today the addition of two new team members. ... and David Raviv will act as head of ... commitment to providing the most secure solutions for the enterprise ... Layer 7 Technologies, a provider of security and management products, ...
(Date:6/26/2015)... ATL Technology, LLC, a top provider of electromechanical contract manufacturing ... headquartered in Springville, Utah , has announced ... corporation with locations in Santa Clara, CA ... ). This acquisition will incorporate MedConx,s manufacturing facility ... existing facility in Costa Rica , resulting ...
(Date:6/25/2015)... N.J. , June 25, 2015  TAKE Solutions ... a patent by the United States Patent and Trademark ... Standardization". This process leverages TAKE Solutions, Clinical Accelerators to ... over 50% (when compared to standardization without the accelerators), ... At the heart of ...
Breaking Biology News(10 mins):HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2TAKE Solutions Awarded Patent By USPTO 2
... 2008. A scientific project funded by the BBVA Foundation and ... Research (CSIC) explored around 100 kilometers of practically uncharted Atlantic ... between the years 2006 and 2007. In the course of ... new hope for the survival of the leatherback turtle. This ...
... an animal model of multiple sclerosis (MS), neuroradiologists and ... have been able to visualize inflammatory tissue damage, most ... the aid of a new contrast medium, Gadofluorine M, ... results in the online edition of the renowned medical ...
... the United States die every year from uncontrolled infections ... are pushing the boundaries of molecular science to find ... simple measure of an immune system protein within 24 ... shock can predict survival in children, yielding a powerful ...
Cached Biology News:Multiple Sclerosis: new MRI contrast medium enables early diagnosis in animal model 2Immune system protein accurate predictor of survival in pediatric septic shock 2Immune system protein accurate predictor of survival in pediatric septic shock 3
Mouse monoclonal [6911] to E. coli K99 pilus ( Abpromise for all tested applications)....
... siRNA Custom Synthesis Service provides ... RNA to knockdown any gene. ... RNA base pairs with terminal ... or other lengths of your ...
Alexa Fluor 647 anti-mouse Qa-2...
...
Biology Products: